Product
Cadonilimab + Anlotinib
1 clinical trial
1 indication
Indication
Esophageal Squamous Cell CarcinomaClinical trial
Safety and Efficacy of Cadonilimab Combined With Anlotinib in Neoadjuvant Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Single Arm, Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2025-05-01